Jin-Ho Choi1, Ravikumar Balasubramanian1, Phil H Lee1, Natalie D Shaw1, Janet E Hall1, Lacey Plummer1, Cassandra L Buck1, Marie-Laure Kottler1, Katarzyna Jarzabek1, Sławomir Wołczynski1, Richard Quinton1, Ana Claudia Latronico1, Catherine Dode1, Tsutomu Ogata1, Hyung-Goo Kim1, Lawrence C Layman1, James F Gusella1, William F Crowley1. 1. Harvard Reproductive Endocrine Sciences Center and Reproductive Endocrine Unit (J.-H.C., R.B., N.D.S., J.E.H., L.P., C.L.B., W.F.C.), and Department of Medicine, Psychiatric, and Neurodevelopmental Genetics Unit (P.H.L.), Analytic and Translational Genetics Unit, Center for Human Genetic Research, Massachusetts General Hospital, and Center for Human Genetic Research (J.F.G.), Massachusetts General Hospital, and Department of Genetics, Harvard Medical School, Boston, Massachusetts Boston, Massachusetts 02114; Department of Genetics (M.-L.K.), University Hospital, Caen, 14003, Caen Cedex, France; Department of Biology and Pathology of Human Reproduction in Bialystok (K.J.), Institute of Animal Reproduction and Food Research, Polish Academy of Sciences, Olsztyn, and Department of Reproduction and Gynecological Endocrinology (S.W.), Medical University of Bialystok, Sklodowskiej 24A, 15-276 Bialystok, Poland; Institute for Genetic Medicine (R.Q.), Newcastle University, Newcastle-upon-Tyne, NE1 3BZ, United Kingdom; Disciplina de Endocrinologia (A.C.L.), Hospital das Clinicas da Faculdade de Medicina, Universidade de Sao Paulo, 05403-900 Sao Paulo, Brazil; Laboratoire de Biochimie et Génétique Moléculaire (C.D.), Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université Paris-Descartes, 75014 Paris, France; Departments of Molecular Endocrinology and Pediatrics (T.O.), Hamamatsu University of School of Medicine, Hamamatsu 431-3192, Japan; Section of Reproductive Endocrinology, Infertility, and Genetics (H.-G.K., L.C.L.), Departments of Obstetrics and Gynecology and Neuroscience and Regenerative Medicine, Medical College of Georgia at Georgia Regents University, Augusta, Georgia 30912; and Department of Pediatrics (J.-H.C.), Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul 138-736, Republic of Korea.
Abstract
CONTEXT: Loss of function (LoF) mutations in more than 20 genes are now known to cause isolated GnRH deficiency (IGD) in humans. Most causal IGD mutations are typically private, ie, limited to a single individual/pedigree. However, somewhat paradoxically, four IGD genes (GNRH1, TAC3, PROKR2, and GNRHR) have been shown to harbor LoF founder mutations that are shared by multiple unrelated individuals. It is not known whether similar founder mutations occur in other IGD genes. OBJECTIVE: The objective of the study was to determine whether shared deleterious mutations in IGD-associated genes represent founder alleles. SETTING: This study was an international collaboration among academic medical centers. METHODS: IGD patients with shared mutations, defined as those documented in three or more unrelated probands in 14 IGD-associated genes, were identified from various academic institutions, the Human Gene Mutation Database, and literature reports by other international investigators. Haplotypes of single-nucleotide polymorphisms and short tandem repeats surrounding the mutations were constructed to assess genetic ancestry. RESULTS: A total of eight founder mutations in five genes, GNRHR (Q106R, R262Q, R139H), TACR3 (W275X), PROKR2 (R85H), FGFR1 (R250Q, G687R), and HS6ST1 (R382W) were identified. Most founder alleles were present at low frequency in the general population. The estimated age of these mutant alleles ranged from 1925 to 5600 years and corresponded to the time of rapid human population expansion. CONCLUSIONS: We have expanded the spectrum of founder alleles associated with IGD to a total of eight founder mutations. In contrast to the approximately 9000-year-old PROKR2 founder allele that may confer a heterozygote advantage, the rest of the founder alleles are relatively more recent in origin, in keeping with the timing of recent human population expansion and any selective heterozygote advantage of these alleles requires further evaluation.
CONTEXT: Loss of function (LoF) mutations in more than 20 genes are now known to cause isolated GnRH deficiency (IGD) in humans. Most causal IGD mutations are typically private, ie, limited to a single individual/pedigree. However, somewhat paradoxically, four IGD genes (GNRH1, TAC3, PROKR2, and GNRHR) have been shown to harbor LoF founder mutations that are shared by multiple unrelated individuals. It is not known whether similar founder mutations occur in other IGD genes. OBJECTIVE: The objective of the study was to determine whether shared deleterious mutations in IGD-associated genes represent founder alleles. SETTING: This study was an international collaboration among academic medical centers. METHODS: IGD patients with shared mutations, defined as those documented in three or more unrelated probands in 14 IGD-associated genes, were identified from various academic institutions, the Human Gene Mutation Database, and literature reports by other international investigators. Haplotypes of single-nucleotide polymorphisms and short tandem repeats surrounding the mutations were constructed to assess genetic ancestry. RESULTS: A total of eight founder mutations in five genes, GNRHR (Q106R, R262Q, R139H), TACR3 (W275X), PROKR2 (R85H), FGFR1 (R250Q, G687R), and HS6ST1 (R382W) were identified. Most founder alleles were present at low frequency in the general population. The estimated age of these mutant alleles ranged from 1925 to 5600 years and corresponded to the time of rapid human population expansion. CONCLUSIONS: We have expanded the spectrum of founder alleles associated with IGD to a total of eight founder mutations. In contrast to the approximately 9000-year-old PROKR2 founder allele that may confer a heterozygote advantage, the rest of the founder alleles are relatively more recent in origin, in keeping with the timing of recent human population expansion and any selective heterozygote advantage of these alleles requires further evaluation.
Authors: Paul I W de Bakker; Roman Yelensky; Itsik Pe'er; Stacey B Gabriel; Mark J Daly; David Altshuler Journal: Nat Genet Date: 2005-10-23 Impact factor: 38.330
Authors: Natalie D Shaw; Stephanie B Seminara; Corrine K Welt; Margaret G Au; Lacey Plummer; Virginia A Hughes; Andrew A Dwyer; Kathryn A Martin; Richard Quinton; Veronica Mericq; Paulina M Merino; James F Gusella; William F Crowley; Nelly Pitteloud; Janet E Hall Journal: J Clin Endocrinol Metab Date: 2011-01-05 Impact factor: 5.958
Authors: Gerasimos P Sykiotis; Lacey Plummer; Virginia A Hughes; Margaret Au; Sadia Durrani; Sadhana Nayak-Young; Andrew A Dwyer; Richard Quinton; Janet E Hall; James F Gusella; Stephanie B Seminara; William F Crowley; Nelly Pitteloud Journal: Proc Natl Acad Sci U S A Date: 2010-08-09 Impact factor: 11.205
Authors: Kimberly H Cox; Luciana M B Oliveira; Lacey Plummer; Braden Corbin; Thomas Gardella; Ravikumar Balasubramanian; William F Crowley Journal: Hum Mol Genet Date: 2018-01-15 Impact factor: 6.150
Authors: Cheng Xu; Andrea Messina; Emmanuel Somm; Hichem Miraoui; Tarja Kinnunen; James Acierno; Nicolas J Niederländer; Justine Bouilly; Andrew A Dwyer; Yisrael Sidis; Daniele Cassatella; Gerasimos P Sykiotis; Richard Quinton; Christian De Geyter; Mirjam Dirlewanger; Valérie Schwitzgebel; Trevor R Cole; Andrew A Toogood; Jeremy Mw Kirk; Lacey Plummer; Urs Albrecht; William F Crowley; Moosa Mohammadi; Manuel Tena-Sempere; Vincent Prevot; Nelly Pitteloud Journal: EMBO Mol Med Date: 2017-10 Impact factor: 12.137
Authors: Tansit Saengkaew; Heena R Patel; Kausik Banerjee; Gary Butler; Mehul T Dattani; Michael McGuigan; Helen L Storr; Ruben H Willemsen; Leo Dunkel; Sasha R Howard Journal: Eur J Endocrinol Date: 2021-10-08 Impact factor: 6.664